Sterling commences large-scale production of Nanologica’s silica particles
Using Nanologica's technology, Sterling will produce the large volumes of NLAB Saga chromatography material needed by Yunbo Technology to perform preparative chromatography.
Global CDMO, Sterling Pharma Solutions has started large-scale production of Nanologica’s silica particles. Nanologica is a nanotechnology company specialising in the development of silica for application in drug development and chromatography.
The company recently signed a long-term supply agreement with Chinese company, Yunbo Technology allowing Sterling to begin production.
Using Nanologica's technology, Sterling will produce the large volumes of NLAB Saga chromatography material needed by Yunbo Technology to perform preparative chromatography with the first batch expected to be ready for testing during 2020.
Andreas Bhagwani, CEO of Nanologica said: "Sterling has over 50 years of experience in cGMP manufacturing for the pharmaceutical industry and very strong process knowledge and expertise in production.
“We feel very comfortable about co-operating with them for scaling up production to completely different volumes than what we manufacture at our site in Södertälje.”
Nanologica announced in February 2018 that it will start manufacturing preparatory chromatography media used in pharmaceutical manufacturing to 'purify' peptides, specifically insulin. Vastly greater amounts of silica are used in preparative chromatography than in analytical chromatography, where Nanologica is active today.
The first commercial batch is expected to be delivered by Sterling during 2021.
Sterling Pharma Solutions, which has sites in the UK and the US, is a well-established manufacturer of active substances, materials and products for customers in the pharmaceutical industry.
Kevin Cook, CEO of Sterling Pharma Solutions said: “Sterling is delighted to be working with Nanologica on this exciting and innovative opportunity. Sterling has rich experience in development and scale-up of complex synthesis in a fully cGMP environment.
“The combination of the Nanologica expertise and technology, together with Sterling’s manufacturing expertise, provides the required combination for successful commercialisation.”
Nanologica has assessed the preparative chromatography market and believes there is significant potential for growth. The company is planning to expand its presence and customer base within the field facilitated by the start of large-scale manufacturing and being able to provide larger samples to customers for testing.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance